{
    "eid": "2-s2.0-84945909920",
    "title": "Rationale and clinical utility of the darunavir\u2013cobicistat combination in the treatment of HIV/AIDS",
    "cover-date": "2015-01-01",
    "subject-areas": [
        {
            "$": "Drug Discovery",
            "@code": "3002"
        },
        {
            "$": "Pharmaceutical Science",
            "@code": "3003"
        },
        {
            "$": "Pharmacology",
            "@code": "3004"
        }
    ],
    "keywords": [
        "Adverse events",
        "Drug\u2013drug interactions",
        "First-line regime",
        "Pharmacoenhancer",
        "Ritonavir",
        "Tolerability"
    ],
    "authors": [
        "Opass Putcharoen"
    ],
    "citedby-count": 12,
    "ref-count": 42,
    "ref-list": [
        "The future of HIV treatment",
        "Guidelines for the Use of Antiretroviral Agents in Hiv-1-Infected Adults and Adolescents",
        "Current status and challenges of antiretroviral research and therapy",
        "Antiretroviral drug development for HIV: Challenges for the future",
        "HIV infection, inflammation, immunosenescence, and aging",
        "Scaling up antiretroviral therapy in resource-limited settings: Adapting guidance to meet the challenges",
        "Mechanisms of disease: Development of antiretroviral drug resistance",
        "Cobicistat: A review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection",
        "Cobicistat (GS-9350): A potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer",
        "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial",
        "Challenges and opportunities in achieving bioequivalence for fixed-dose combination products",
        "Comb Prod Ther",
        "Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A",
        "Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation",
        "The structure and function of the aspartic proteinases",
        "Active human immunodeficiency virus protease is required for viral infectivity",
        "Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 \u00c5 resolution",
        "Cardiovascular risk associated with HIV therapy",
        "Boosting HIV treatment options: Good news, new challenges",
        "Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor",
        "Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier",
        "Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48",
        "Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-na\u00efve patients in the ARTEMIS trial",
        "Darunavir: A review of its use in the management of HIV-1 infection",
        "Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs",
        "Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir",
        "Ritonavir-boosted protease inhibitors in HIV therapy",
        "Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation",
        "Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting",
        "Pharmacokinetics and pharmacodynamics of gs-9350: A novel pharmacokinetic enhancer without Anti-HIV activity",
        "Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection",
        "Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 results",
        "Janssen Therapeutics",
        "Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-na\u00efve and - Experienced patients",
        "Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function",
        "Bioequivalence of a darunavir/cobicistat fixed-dose combination tablet versus single agents and food effect in healthy volunteers",
        "Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment",
        "J Int AIDS Soc",
        "Cobicistat-boosted darunavir in HIV-1-infected adults: Week 48 results of a Phase IIIb, open-label single-arm trial",
        "Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: A randomized phase 2 study"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Thai Red Cross Agency",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}